COMMUNIQUÉS West-GlobeNewswire

Beeline Medicines Announces Positive Topline Results from Global Phase 2 Study of Afimetoran in Systemic Lupus Erythematosus
09/09/2026
– Study met its primary endpoint, with afimetoran demonstrating higher SRI-4 response rates versus placebo at Week 48 (p-value <0.001 across all dose groups) – – Secondary endpoints demonstrated improvements [...]
ABBYY Study Finds Business Leaders Disagree on Who Has Ultimate Responsibility When AI Goes Wrong
09/09/2026
2026 ABBYY Who Answers for AI: The Governance Gap reveals that governance is struggling to keep pace with innovation AI ROI is falling short of expectations and data quality is the top reason 70% say data governance [...]
Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society
09/09/2026
IRVINE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation highlighting the long-term safety and efficacy of tegoprubart in preventing [...]
Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment
09/09/2026
No serious adverse events reported to date Preliminary efficacy results expected in late 2026 or early 2027 MIAMI, Fla. And BOTHELL, Wash., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (" [...]
Invisible Balance Disorders Affect Millions
09/09/2026
ASHA Joins National Effort To “Make Vestibular Visible” for September Awareness Week Rockville, Md., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Balance disorders are common, often disabling, and frequently misunderstood and [...]
Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference
09/09/2026
MELBOURNE, Australia and INDIANAPOLIS, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) advises that Dr. Christian Behrenbruch, Managing Director and Group CEO and Kevin [...]
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management
09/09/2026
Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind’s Technosphere ® inhalation technology MannKind to receive an equity interest and potential royalties while providing [...]
RadNet to Host Free Prostate Cancer Webinar on September 19, 2026
09/09/2026
Public event brings together a radiologist, urologist and robotic surgeon, and a prostate cancer survivor for an informative conversation and live Q&A about prostate cancer screening, diagnosis and treatment LOS [...]
RadNet, Inc. to Present at the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16th, 2026
09/09/2026
LOS ANGELES, Sept. 09, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated [...]
Allogenetics Raises €3.8 Million Pre-Series A to Advance Novel Ex Vivo Gene Therapy Approach to Improve Organ Transplantation Outcomes
09/09/2026
Financing will support lead program ALG-115 through IND-enabling studies toward clinical evaluation in lung transplantation Round was led by NBank Capital with participation from CARMA FUND, Life Science Valley [...]
Athernal Bio Secures Innovate UK Grant to Advance Cancer Interception in High-Risk Leukaemia
09/09/2026
Innovate UK grant supports Athernal’s mission to intercept high-risk leukaemia before cancer develops Funding reflects growing confidence in cancer interception as an emerging therapeutic approach London, UK, September [...]
Syngenta and Amoéba Seal Exclusive European Distribution Deal, Aiming to Bring a Breakthrough Biofungicide to Cereal Growers
09/09/2026
Basel, Switzerland and Chassieu, France, , Sept. 09, 2026 (GLOBE NEWSWIRE) -- The exclusive agreement will span the cereals market across the European Union, the United Kingdom, Ukraine and Switzerland, with first [...]
Syngenta et Amoéba ont conclu un accord de distribution exclusif en Europe pour proposer aux céréaliers une innovation biofongicide
09/09/2026
Bâle (Suisse) et Chassieu (France) , 09 sept. 2026 (GLOBE NEWSWIRE) -- Syngenta et Amoéba ont conclu un accord de distribution exclusif en Europe pour proposer aux céréaliers une innovation biofongicide Cet accord [...]
Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial
09/09/2026
- Treatment with oral infigratinib for 52 weeks in PROPEL 3 resulted in favorable trends against placebo in clinically meaningful exploratory endpoints including sleep apnea and otitis media events Stabilization of [...]
ViaNautis Bio welcomes SCI Ventures as new investor, expanding CNS portfolio into spinal cord injury
09/09/2026
Investment supports application of ViaNautis’ polyNaut ® platform to regenerative therapies for spinal cord injury, where targeted delivery remains a huge barrier Adds a new high-value CNS indication and provides [...]
Biocomposites to host industry symposium and present new STIMULAN® data at EBJIS-MSIS 2026
09/09/2026
Industry symposium to explore local delivery of combination antibiotics across spine and arthroplasty Poster showcases the efficacy of STIMULAN ® calcium sulfate beads, loaded with a combination of Gram-positive and [...]
Allegro’s Hydrocelin significantly improves knee osteoarthritis pain and function in clinical trial
09/09/2026
Nanotechnology-based injection significantly improved knee pain and function with favorable safety and efficacy sustained over 6 months following a single administration Feasibility trial in Belgium completed [...]
Pharming Group to participate in September investor conferences
09/09/2026
Leiden, the Netherlands, September 9, 2026: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced that its management will participate in the following investor conferences in the [...]
GENFIT Highlights Long-Term Commercial Opportunity for its MASH Diagnostics Technology
09/09/2026
Simple, reliable and scalable blood-based testing could identify patients with at-risk MASH among nearly 90 million U.S. individuals receiving medical attention due to MASLD-related risk factors IQVIA estimates U.S peak [...]

Pages